1207-P: Hepatic Steatosis Index and Fibrosis-4 Scores in Relation to Cardiometabolic Risk in Healthy Offspring of Parents with Type 2 Diabetes

Abstract

We explored the association between nonalcoholic fatty liver disease and cardiometabolic risk and the impact of race/ethnicity among healthy offspring of parents with type 2 diabetes (T2D) . These post hoc analyses were conducted on baseline data from the Pathobiology of Prediabetes in a Biracial Cohort (POP-ABC study) . Participants (N 376) were normoglycemic (NGT) White (N159) and Black (N 217) adults, aged 18-75 years, with at least 1 parent with T2D. The presence of hepatic steatosis was estimated by hepatic steatosis index (HSI; 8 × ALT/AST + BMI + 2 if female) ; and for hepatic fibrosis, fibrosis-4 score (FIB-4; [age × AST]/[platelets count × √ALT]) . We determined the association between HSI and Fib-4 vs. markers of the metabolic syndrome (MetS) , using a modified definition in our NGT cohort (waist≥100cm in men, ≥88 cm in women; BP ≥ 120/80mmHg, triglycerides ≥150mg/dl, HDL ≤40 in men, ≤50 in women) . HSI did not differ by sex or race, showed no correlation with age, but correlated significantly with MetS components: waist (r= 0.77, P<0.0001; systolic BP (r= 0.246, P <0.0001;) ; HDL (r= −0.224, P<0.0001; triglycerides (r= 0.11, P= 0.0009) . HSI increased cumulatively with MetS markers. FIB-4 score showed no sex or ethnic disparities, and correlated with BMI (r= −0.17, P= 0.0015) , total fat mass (r= −0.13, P= 0.02) and HDL (r=0.11, P=0.044) but not waist, BP or triglycerides. Unlike HSI, Fib-4 showed no cumulative association with MetS markers. These findings were similar in Black and White participants. Our data from POPABC study indicate that HSI is an informative early marker of the link between hepatic steatosis and cardiometabolic risk in normoglycemic Black and White offspring of parents withT2D. Disclosure B.Colon barreto: None. K.Siwakoti: None. C.Edeoga: None. S.Ebenibo: None. S.Dagogo-jack: Consultant; AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Inc., Medtronic, Merck & Co., Inc., Sanofi. Funding American Diabetes Association (7-07-MN-13) ; National Institutes of Health (R01 DK067269)